Management of Hypotension in Patients on Beta-Blockers

Immediate Action and Assessment

When systolic blood pressure falls below 100 mmHg, metoprolol should be withheld until blood pressure stabilizes above this threshold, as established by the European Society of Cardiology 1, 2
The European guidelines explicitly identify hypotension (systolic BP <100 mmHg) as a contraindication to beta-blocker administration, particularly when combined with other risk factors, according to the European Society of Cardiology 1, 2
Check for signs of hypoperfusion, such as altered mental status, oliguria, cool extremities, dizziness, lightheadedness, or blurred vision, as recommended by the American Heart Association 3
Measure heart rate, as bradycardia (HR <50-60 bpm) combined with hypotension represents a contraindication to continued beta-blocker therapy, according to the American College of Cardiology 3

Continue holding metoprolol until systolic BP consistently exceeds 100 mmHg, as demonstrated by the POISE trial and recommended by the European Society of Cardiology 1, 2
Consider reducing the metoprolol dose by 50% (from 25mg to 12.5mg daily) rather than completely discontinuing, to maintain some beta-blockade benefit while reducing hypotensive risk, as suggested by the American Heart Association 3
Complete discontinuation of metoprolol in patients with coronary artery disease or heart failure increases mortality risk 2.7-fold compared to continuous use, according to the European Society of Cardiology 3

Monitor blood pressure and heart rate every 4-6 hours initially, and watch for symptoms of worsening heart failure, as recommended by the American College of Cardiology 3
Restart metoprolol only when systolic BP consistently >100 mmHg for at least 24 hours, heart rate >55-60 bpm if bradycardia was present, and patient is asymptomatic from cardiovascular standpoint, according to the European Society of Cardiology 1, 2, 3
Begin at 12.5mg daily and titrate slowly over weeks, monitoring BP and HR at each visit, as suggested by the American Heart Association 3

Never abruptly discontinue metoprolol, especially in patients with coronary artery disease, as abrupt cessation can cause severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias, with documented 50% mortality rates in some studies, according to the European Society of Cardiology 3
Do not give metoprolol if signs of cardiogenic shock are present, such as age >70 years, HR >110 or <60 bpm, evidence of heart failure, or Killip class >1, as recommended by the European Society of Cardiology 1, 2

In patients on combined losartan, metoprolol, and verapamil who develop systolic blood pressure < 100 mmHg, verapamil should be held completely. [4][5]

Losartan (an ARB) does not share the dangerous interaction profile of verapamil with beta‑blockers and provides a mortality benefit in hypertensive individuals with heart failure. 6
Consequently, losartan should be the last medication reduced when managing hypotension, because it does not cause bradycardia and has fewer hazardous drug interactions. 6

When discontinuing verapamil, clinicians should consider replacing it with a dihydropyridine calcium‑channel blocker such as amlodipine, which does not affect heart rate and does not interact adversely with beta‑blockers. 6